Corporate Banner
Satellite Banner
Molecular & Clinical Diagnostics
Scientific Community
 
Become a Member | Sign in
Home>News>This Article
  News
Return

Biocartis and Hospital del Mar Join Forces

Published: Monday, October 21, 2013
Last Updated: Sunday, October 20, 2013
Bookmark and Share
License agreement to develop diagnostic colon cancer test.

Biocartis and Hospital del Mar have announced their license agreement on the EGFR biomarker for colon cancer.

This agreement enables Biocartis to develop a new colon cancer test, whereby a specific EGFR mutation can be rapidly and accurately detected in patients, which will enable doctors to recommend personalized therapy.

Innovative platforms and tests for cancer diagnosis
Biocartis is active in molecular diagnostics and develops innovative diagnostic platforms, which allow for efficient disease detection. Biocartis also develops a wide range of clinically relevant tests for various therapeutic areas with a primary focus on cancer diagnosis.

EGFR: new biomarker for colon cancer
Recently Dr Montagut and her team (Dr Albanell’s department of Medical Oncology, Hospital del Mar) showed that colon cancer patients with an S492R-mutation in the EGFR (Epidermal Growth Factor Receptor) can’t be helped with the colon cancer drug cetuximab.

The EGFR mutation makes the tumours resistant to this treatment, whilst they remain sensitive to treatment with panitumumab. These results were published in the leading scientific journal Nature Medicine.

Rapid diagnosis results in personalized therapy
"Our agreement with Biocartis represents a crucial step in translating our relevant scientific findings to benefit the patient,” according to Clara Montagut, associated doctor, Oncology department, Hospital del Mar and researcher at the IMIM (Hospital del Mar Medical Research Institute).

The collaboration with Hospital del Mar enables Biocartis to develop a colon cancer test for a fast and accurate detection of the EGFR mutation.

"This new biomarker enables us to develop a unique combination of tests for the detection of colon cancer, which can be analyzed on our state-of-the-art molecular diagnostic platforms," added Geert Maertens, Chief Scientific Officer at Biocartis.

Maertens continued, “The detection of this biomarker in colon cancer patients ensures that personalized therapy can be applied faster and more efficiently.”


Further Information

Join For Free

Access to this exclusive content is for Technology Networks Premium members only.

Join Technology Networks Premium for free access to:

  • Exclusive articles
  • Presentations from international conferences
  • Over 3,200+ scientific posters on ePosters
  • More than 4,600+ scientific videos on LabTube
  • 35 community eNewsletters


Sign In



Forgotten your details? Click Here
If you are not a member you can join here

*Please note: By logging into TechnologyNetworks.com you agree to accept the use of cookies. To find out more about the cookies we use and how to delete them, see our privacy policy.

Related Content

Biocartis to Present BRAF Liquid Biopsy Data at ASCO Annual Meeting
BRAF mutations identified by Idylla™ from circulating tumor DNA in plasma associated with treatment response.
Thursday, June 04, 2015
Biocartis and Fast-track Diagnostics Sign Strategic Collaboration
Both Companies aim to develop a range of multiplex tests on the Biocartis Idylla™ system each detecting a range of infectious disease pathogens.
Wednesday, May 27, 2015
Biocartis And Microbiome Collaborate
Collaboration aims to develop rapid and sensitive sepsis test.
Thursday, April 09, 2015
Biocartis Spins Out Life Sciences Multiplex Platform Evalution into Mycartis
Company has combined its Swiss Evalution business unit with Pronota NV to form MyCartis.
Saturday, September 06, 2014
Biocartis Raises EUR 64.5 Million
Investment supports commercial roll-out of Idylla™, Biocartis’ flagship molecular diagnostics system, and the development of the system’s menu of diagnostics tests.
Friday, September 05, 2014
Invetech and Biocartis Announce Biomarker Collaboration
Agreement supporting global development and manufacture of instrument to analyze protein and nucleic acid biomarkers continues multi-year relationship.
Wednesday, April 16, 2014
Biocartis and VIB Join Forces
Company will develop a new CRC assay for MSI biomarker detection.
Monday, December 09, 2013
Biocartis Announces the End of its Alliance with bioMérieux
Agreement for the development and commercialization of the integrated molecular biology system, Idylla™.
Friday, November 29, 2013
Biocartis Announces Completion of EUR 30 Million Series E Equity Fundraising
Company poised for 2014 commercial launch.
Thursday, November 07, 2013
Scientific News
Proteins in Blood of Heart Disease Patients May Predict Adverse Events
Nine-protein test shown superior to conventional assessments of risk.
£14m EU Project To Aid Meningitis Diagnosis and Cut Antibiotic Use
An international team of doctors are aiming to develop a rapid test to allow medics to quickly identify bacterial infection in children.
Bringing AFM to Medical Diagnostics
Company has announced that its NanoWizard® AFM and ForceRobot® systems are being used in the field of medical diagnostics in the Supersensitive Molecular Layer Laboratory of POSTECH in Korea.
Scientific Gains May Make Electronic Nose the Next Everyday Device
UT Dallas team breathes new life into possibilities by using CMOS integrated circuits technology.
Electronic Sensor Tells Dead Bacteria From Live
The sensor, which measures 'osmoregulation', is a potential future tool for medicine and food safety.
Diagnosing Systemic Infections Quickly, Reliably
Team develop rapid and specific diagnostic assay that could help physicians decide within an hour whether a patient has a systemic infection and should be hospitalized for aggressive intervention therapy.
A Future Tool for Medicine, Food Safety
A new type of electronic sensor that might be used to quickly detect and classify bacteria for medical diagnostics and food safety has passed a key hurdle by distinguishing between dead and living bacteria cells.
Genome Sequencing Helps Determine End of TB Outbreak
Using genome sequencing, researchers from the University of British Columbia, along with colleagues at the Imperial College in London, now have the ability to determine when a tuberculosis (TB) outbreak is over.
What Makes a Good Scientist?
It’s the journey, not just the destination that counts as a scientist when conducting research.
Shimmer Partners with Harvard's Wyss Institute
Partnership to support ongoing research focused on remote patient monitoring using wearable sensing technology.
SELECTBIO

SELECTBIO Market Reports
Go to LabTube
Go to eposters
 
Access to the latest scientific news
Exclusive articles
Upload and share your posters on ePosters
Latest presentations and webinars
View a library of 1,800+ scientific and medical posters
3,200+ scientific and medical posters
A library of 2,500+ scientific videos on LabTube
4,600+ scientific videos
Close
Premium CrownJOIN TECHNOLOGY NETWORKS PREMIUM FOR FREE!